Prescription of Letrozole for Uterine Myoma

The PLUM Study is a randomized, double-blinded, 2-arm, parallel-group, placebo-controlled trial is designed to compare the efficacy of letrozole versus placebo on leiomyoma-related symptoms and quality of life as well as leiomyoma and uterine size.

Trial Details

NCT ID
NCT06143631
Phase
PHASE4
Sponsor
University of California, San Francisco
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • Letrozole 2.5mg
  • Placebo
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • San Francisco, California, United States|37.77493,-122.41942
  • Rochester, Minnesota, United States|44.02163,-92.4699
  • Jackson, Mississippi, United States|32.29876,-90.18481
  • Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

  • At least 21 and less than 54 years of age (to focus on an adult, premenopausal population)
  • Female sex, based on sex identified on their birth certificate (no other gender requirements)
  • Have uterine leiomyomata that have been visualized on pelvic imaging (i.e., ultrasound or MRI) in the last 24 months
  • Report symptoms associated with leiomyomata such as heavy uterine bleeding, pelvic pressure or discomfort, urinary or bowel abnormalities, or dyspa…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →